Search Result

All Related Services Other Content

Home Crystal Pharmatech's Mol2Med™ First-Time-Right approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, this innovative approach sets the foundation for optimized drug development and success beyond.
Solid Form Screening and Selection Solid form is a general term that refers to both crystalline and amorphous materials. The solid form will impact active pharmaceutical ingredient (API) development properties such as solubility, dissolution rate, stability, hygroscopicity, and bioavailability.
Case Study 1: Indinavir - Early Salt Form Change BackgroundIt has been reported that the solid form of active pharmaceutical ingredients (APIs) has significantly impacted quality and consistency of the final dosage form for drug development compound...
Whitepaper
Biologics Characterization and CMC Analytics CBS provides analytical and CMC services and solutions for the development, manufacturing and approval of new mAbs and therapeutical proteins and their biosimilars.
High-Resolution Mass Spectrometry High-Resolution Mass SpectrometryCMC: Experts in BLA filings for drugs at biophysical/chemical section using LC-MS under regulatory guideline for drug approval with several large pharmaPreclinical: Ex...
First-Time-Right 3-STEP Approach Crystal Pharmatech are a specialized CRO/CDMO focused on Solid State Research, Pre-Formulation, Formulation Development and Manufacturing. Our strength is our focus and expertise in these specialties...
Crystal Pharmatech Formulation Forum Platform for collaborative learning across the pharmaceutical industry
Bioanalytical and Biomarker Services With more than 100 years of combined industry experience of our leadership team and three GLP compliant laboratories, we are ready for all your current and emerging bioanalytical needs.
Highlights
Holistic Polymorph Screening - Identify the Lead Crystal Form and Accelerate CMC Progress From early developability to late-stage specifications—polymorph/salt-cocrystal strategy, SCXRD/MicroED solutions, solvent & pathway design, drug-product form control, ASD crystalline-form limits...
DNA Synthesis
RNA Synthesis